Axitinib is under clinical development by Pfizer and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Axitinib’s likelihood of approval (LoA) and phase transition for Paraganglioma (Glomus Jugulare Tumor) took place on 01 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Axitinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Axitinib overview

Axitinib (Inlyta) is an anti-cancer agent. It is formulated as film-coated tablets and tablets for oral route of administration. It is indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.Inlyta in combination with avelumab and pembrolizumab is indicated for the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC).

The drug candidate is under development for the treatment of advanced melanoma, solid tumors including salivary gland cancers (SGCs) of the upper aerodigestive tract, paraganglioma, angiosarcoma, soft tissue sarcoma, chondrosarcoma, osteosarcoma, Ewing sarcoma, leiomyosarcoma, peripheral nerve sheath tumor (neurofibrosarcoma), rhabdomyosarcoma, synovial sarcoma, pleomorphic liposarcoma, neuroendocrine tumours of non pancreatic origin, recurrent glioblastoma, spindle cell squamous cell carcinoma , salivary gland cancer, gastrointestinal stromal tumor (GIST), clear cell squamous cell carcinoma , chordoma, metastatic transitional (urothelial) tract cancer, bladder cancer, urethral cancer, ureter cancer, non-small cell lung cancer, prostate cancer and ductal adenocarcinoma. It was also under development for the treatment of Kaposi sarcoma, metastatic melanoma, metastatic uveal melanoma, adrenocortical carcinoma, glioblastoma multiforme, thyroid cancer, metastatic breast cancer, metastatic colorectal cancer, gastric cancer, myelodysplastic syndrome, acute myelocytic leukemia, renal cell carcinoma, head and neck squamous cell carcinoma,  metastatic pancreatic cancer, and metastatic hepatocellular carcinoma.

Pfizer overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

Quick View Axitinib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Axitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.